Diadema Partners’s Pyxis Oncology PYXS Stock Holding History

Diadema Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$333K	–	181
2025 Q3	$333K	Buy	+150,000	New	+$216K	0.09%	106

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Diadema Partners's PYXS Position: Q4 2025 in Review

Diadema Partners sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 150,000 shares — an estimated $333K sold.

Diadema Partners first reported a position in PYXS in Q3 2025 and held it in 1 quarter. The position peaked at $333K in Q3 2025. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

Diadema Partners reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 150,000 Pyxis Oncology shares in Q4 2025, an estimated $333K.
Diadema Partners first reported a position in Pyxis Oncology in Q3 2025 and held it in 1 quarter.
Diadema Partners's Pyxis Oncology position peaked at $333K in Q3 2025.
79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.